Evidence map›Paper›PMID 37513105›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Radiofluorination of an Anionic, Azide-Functionalized Teroligomer by Copper-Catalyzed Azide-Alkyne Cycloaddition.

Barbara Wenzel, Maximilian Schmid, Rodrigo Teodoro, Rareş-Petru Moldovan, Thu Hang Lai, Franziska Mitrach, Klaus Kopka, Björn Fischer, Michaela Schulz-Siegmund, Peter Brust and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. [Molecules (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Barbara WenzelDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.ORCID 0000-0001-7390-3575
Maximilian SchmidInstitute of Pharmacy, Pharmaceutical Technology, Leipzig University, 04317 Leipzig, Germany.ORCID 0000-0001-7250-1582
Rodrigo TeodoroDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.
Rareş-Petru MoldovanDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.ORCID 0000-0003-3119-7945
Thu Hang LaiDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.ORCID 0000-0001-8157-8979
Franziska MitrachInstitute of Pharmacy, Pharmaceutical Technology, Leipzig University, 04317 Leipzig, Germany.
Klaus KopkaDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.ORCID 0000-0003-4846-1271
Björn FischerInstitute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0002-2868-8754
Michaela Schulz-SiegmundInstitute of Pharmacy, Pharmaceutical Technology, Leipzig University, 04317 Leipzig, Germany.ORCID 0000-0003-1340-1850
Peter BrustDepartment of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 04318 Leipzig, Germany.ORCID 0000-0001-5555-7058
Michael C HackerInstitute of Pharmacy, Pharmaceutical Technology, Leipzig University, 04317 Leipzig, Germany.ORCID 0000-0002-4776-2294
Helmholtz-Zentrum Dresden-Rossendorf · DEHeinrich Heine University Düsseldorf · DELeipzig University · DE

Funding

Europäischer Fonds für regionale Entwicklung (EFRE) 100344836Sächsische Aufbaubank 100344836
6 · The paper itself

Abstract

This study describes the synthesis, radiofluorination and purification of an anionic amphiphilic teroligomer developed as a stabilizer for siRNA-loaded calcium phosphate nanoparticles (CaP-NPs). As the stabilizing amphiphile accumulates on nanoparticle surfaces, the fluorine-18-labeled polymer should enable to track the distribution of the CaP-NPs in brain tumors by positron emission tomography after application by convection-enhanced delivery. At first, an unmodified teroligomer was synthesized with a number average molecular weight of 4550 ± 20 Da by free radical polymerization of a defined composition of methoxy-PEG-monomethacrylate, tetradecyl acrylate and maleic anhydride. Subsequent derivatization of anhydrides with azido-TEG-amine provided an azido-functionalized polymer precursor (

Indexed as

18F-polymerclick reactionCuAACfluorine-18PEG-[18F]FPyKYNEteroligomer

Identifiers

PMID37513105
PMCPMC10385230
OpenAlexW4384827935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.